Skip to main content
Top
Published in: International Cancer Conference Journal 3/2016

01-07-2016 | Case report

Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer

Authors: Takeshi Yamada, Hayato Kan, Satoshi Matsumoto, Michihiro Koizumi, Seiichi Shinji, Akihisa Matsuda, Aya Yamagishi, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Eiji Uchida

Published in: International Cancer Conference Journal | Issue 3/2016

Login to get access

Abstract

We report a case involving a patient with colon cancer who underwent 5-fluorouracil (5-FU) rechallenge and maintained an oncological effect for a long period after encephalopathy caused by 5-FU. Our patient was a 61-year-old man who was diagnosed with adenocarcinoma of the ascending colon with direct liver invasion. He underwent right hemicolectomy with partial liver resection followed by adjuvant chemotherapy with modified FOLFOX6 (mFOLFOX6). Ten months after completion of mFOLFOX6, his carcinoembryonic antigen concentration increased, and ascites was revealed by computed tomography 2 months later. We started FOLFIRI, and he was taken to our hospital by ambulance because of loss of consciousness 10 days after the start of the third cycle of FOLFIRI. Laboratory investigations showed hyperammonemia and elevations of his serum creatinine and blood urea nitrogen concentrations. Brain computed tomography demonstrated no abnormalities. Transfusion of 1500 ml of crystalloid fluid resulted in gradual recovery over the next 12 h. His ammonia concentration decreased to a normal level. Twelve days after onset of the encephalopathy, we restarted FOLFIRI, but the dose of continuous 5-FU was decreased by 20 %. The patient’s carcinoembryonic antigen concentration considerably decreased from 376.5 to 19.9 ng/ml, and his ascites disappeared. Nineteen months after the resumption of FOLFIRI, he underwent 34 courses of FOLFIRI and maintained stable disease. The encephalopathy did not recur.
Literature
1.
go back to reference Advani PP, Fakih MG (2011) 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine. Anticancer Res 31:335–338PubMed Advani PP, Fakih MG (2011) 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine. Anticancer Res 31:335–338PubMed
2.
go back to reference Liaw CC, Wang HM, Wang CH et al (1999) Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10:275–281CrossRefPubMed Liaw CC, Wang HM, Wang CH et al (1999) Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10:275–281CrossRefPubMed
3.
go back to reference Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464–465CrossRefPubMedPubMedCentral Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464–465CrossRefPubMedPubMedCentral
4.
go back to reference Sharief U, Perry DJ (2009) Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 8:163–165CrossRefPubMed Sharief U, Perry DJ (2009) Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 8:163–165CrossRefPubMed
5.
go back to reference Kim YA, Chung HC, Choi HJ et al (2006) Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36:55–59CrossRefPubMed Kim YA, Chung HC, Choi HJ et al (2006) Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36:55–59CrossRefPubMed
6.
go back to reference Skelton MR, Goldberg RM, O’Neil BH (2007) A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 6:386–388CrossRefPubMed Skelton MR, Goldberg RM, O’Neil BH (2007) A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 6:386–388CrossRefPubMed
7.
go back to reference Moore DH, Fowler WC Jr, Crumpler LS (1990) 5-Fluorouracil neurotoxicity. Gynecol Oncol 36:152–154CrossRefPubMed Moore DH, Fowler WC Jr, Crumpler LS (1990) 5-Fluorouracil neurotoxicity. Gynecol Oncol 36:152–154CrossRefPubMed
9.
go back to reference Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed
10.
go back to reference Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMed Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMed
11.
go back to reference Thomas SA, Tomeh N, Theard S (2015) Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res 35:6761–6763PubMed Thomas SA, Tomeh N, Theard S (2015) Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res 35:6761–6763PubMed
Metadata
Title
Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer
Authors
Takeshi Yamada
Hayato Kan
Satoshi Matsumoto
Michihiro Koizumi
Seiichi Shinji
Akihisa Matsuda
Aya Yamagishi
Yasuyuki Yokoyama
Goro Takahashi
Takuma Iwai
Eiji Uchida
Publication date
01-07-2016
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 3/2016
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0243-0

Other articles of this Issue 3/2016

International Cancer Conference Journal 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine